Summary of COVID-19 ibrutinib studies

1. Coutre et al., Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study

46 patient ibrutinib late treatment RCT: 9% higher mortality (p=1), 9% lower hospital discharge (p=1), and 35% lower progression (p=0.7).
RCT 46 hospitalized patients with severe COVID-19 showing no significant differences with ibrutinib treatment.
Mar 2022, Open Forum Infectious Diseases, https://academic.oup.com/ofid/article/doi/10.1093/ofid/ofac104/6553342, https://c19p.org/coutre